ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer: final overall survival (OS) analysis
A. Clamp(The Christie NHS Foundation Trust), Jonathan A. Ledermann(London Cancer), Axel Walther, James D. Brenton(Cambridge University Hospitals NHS Foundation Trust), Sudha Sundar(University of Birmingham), Roshan Agarwal(Imperial College Healthcare NHS Trust), Sarah P. Blagden(Churchill Hospital), Agnieszka Michael(University of Surrey), Cristiana Sessa(Institute of Oncology Research), Domenico Radice(University College London), Mahesh Kb Parmar(MRC Clinical Trials Unit at UCL), Laura Murphy(MRC Clinical Trials Unit at UCL), Richard Kaplan(MRC Clinical Trials Unit at UCL), Aleksandra Gentry-Maharaj(MRC Clinical Trials Unit at UCL), Dearbhaile O'Donnell(Cancer Trials Ireland), Rosemary Lord(Clatterbridge Cancer Centre NHS Foundation Trust), Audrey Cook, Francesca Schiavone(MRC Clinical Trials Unit at UCL)
Cited by 1
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k